Pustular psoriasis eruption with dabrafenib, a BRAF inhibitor

Journal of Dermatological Treatment

Volumn 27, Issue 5, 2016, Pages 418-421

  Fawaz, Bilal ^a   Dickson, Lauren ^a   Menter, Alan ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

adverse; cutaneous; medication; reaction; toxicity

Indexed keywords

B RAF KINASE; BETAINE DERIVATIVE; BEVACIZUMAB; CARBOPLATIN; DABRAFENIB; EDETATE DISODIUM; ETANERCEPT; HYDROCORTISONE; HYPOCHLORITE SODIUM; MITOGEN ACTIVATED PROTEIN KINASE; MOMETASONE FUROATE; NYSTATIN; PACLITAXEL; SODIUM SULFATE; STEROID; TUMOR NECROSIS FACTOR; WATER; ZINC OXIDE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR;

ACANTHOSIS; ADULT; ARTICLE; CALLUS; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL TRIAL (TOPIC); DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME INHIBITION; ERYTHEMA; FEMALE; HUMAN; HYPERKERATOSIS; LEUKOCYTE AGGREGATION; LIVER FUNCTION TEST; LUNG ADENOCARCINOMA; LYMPHOCYTIC INFILTRATION; MIDDLE AGED; NEUTROPHIL; PAPULE; PARAKERATOSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; PUSTULE; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG ERUPTIONS; PSORIASIS;

ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PSORIASIS;

EID: 84963502509     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2016.1157258     Document Type: Article

References (15)

1. C.Peyssonnaux, A.Eychene The Raf/MEK/ERK pathway:new concepts of activation. Biol Cell. 2001;93:53–62.
2. H.Davies, G.R.Bignell, C.Cox,. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.
3. N.Dhomen, R.Marais BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. 2009;23:529–45.
4. P.B.Chapman, A.Hauschild, C.Robert,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
5. A.Hauschild, J.J.Grob, L.V.Demidov, et al. Dabrafenib in BRAF-mutated metastatic melanoma:a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.
6. G.Carlos, R.Anforth, A.Clements,. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151:1103–9.
7. W.Chan, D.A.Vorobiof. Dupuytren's contractures associated with the BRAF inhibitor vemurafenib:a case report. J Med Case Rep. 2015;9:158.
8. V.Sibaud, C.Chevreau. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib. Joint Bone Spine. 2014;81:373–4.
9. M.Patel, N.R.Freeman, S.Dhaliwal,. The prevalence of Dupuytren contractures in patients with psoriasis. Clin Exp Dermatol. 2014;39:894–9.
10. C.Blandizzi, A.Gionchetti, A.Armuzzi,. The role of tumor necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol. 2014;27:1–10.
11. L.S.Verjee, J.S.Verhoekx, J.K.Chan, et al. Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. Proc Natl Acad Sci USA. 2013;110:E928–37.
12. J.S.Wilmott, L.E.Haydu, A.M.Menzies,. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. J Immunol. 2014;192:2505–13.
13. P.I.Poulikakos, C.Zhang, G.Bollag,. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427–30.
14. A.Mavropoulos, E.I.Rigopoulou, C.Liaskos,. The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis. Clin Dev Immunol. 2013;2013:569751.
15. P.P.Roux, J.Blenis ERK and p38 MAPK-activated protein kinases:a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004;68:320–44.